U.S. Markets close in 4 hrs 12 mins
  • S&P 500

    4,354.94
    -78.05 (-1.76%)
     
  • Dow 30

    34,022.00
    -562.88 (-1.63%)
     
  • Nasdaq

    14,705.50
    -338.47 (-2.25%)
     
  • Russell 2000

    2,179.31
    -57.56 (-2.57%)
     
  • Crude Oil

    70.93
    -1.04 (-1.45%)
     
  • Gold

    1,763.30
    +11.90 (+0.68%)
     
  • Silver

    22.36
    +0.07 (+0.29%)
     
  • EUR/USD

    1.1732
    0.0000 (-0.0000%)
     
  • 10-Yr Bond

    1.3230
    -0.0470 (-3.43%)
     
  • Vix

    25.03
    +4.22 (+20.28%)
     
  • GBP/USD

    1.3661
    -0.0076 (-0.5533%)
     
  • USD/JPY

    109.4810
    -0.4140 (-0.3767%)
     
  • BTC-USD

    44,590.88
    -3,435.44 (-7.15%)
     
  • CMC Crypto 200

    1,095.57
    -38.81 (-3.42%)
     
  • FTSE 100

    6,908.48
    -55.16 (-0.79%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

XOMA Buys Royalty, Milestone Interest In Checkmate's Vidutolimod From Kuros Biosciences

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • XOMA Corporation (NASDAQ: XOMA) has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals Inc's (NASDAQ: CMPI) vidutolimod (CMP-001), for $7.0 million upfront plus 6.5 million as sales milestones.

  • Checkmate currently is enrolling patients in a study with anti-PD-1 refractory advanced melanoma in combination with Bristol Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab), a PD-1 blocking antibody.

  • Checkmate also is pursuing a Phase 2/3 study in front-line melanoma patients in combination with Opdivo and a study in patients with head and neck cancer and is planning a study in three indications in collaboration with Regeneron in non-melanoma skin cancers.

  • Under the terms of the agreement, XOMA could receive up to $25 million in pre-commercial milestones.

  • Kuros will be eligible to receive certain sales milestone payments from XOMA based on net sales of vidutolimod.

  • Price Action: XOMA shares closed at $32.39 on Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.